Scarica l'app Stockscreener
0.9899
11.60%
0.1029
Dopo l'orario di chiusura:
.99
0.000100
+0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALVR Giù?
Forum
Previsione
Precedente Chiudi:
$0.887
Aprire:
$0.89
Volume 24 ore:
694.01K
Relative Volume:
3.64
Capitalizzazione di mercato:
$111.67M
Reddito:
-
Utile/perdita netta:
$-168.86M
Rapporto P/E:
-0.553
EPS:
-1.79
Flusso di cassa netto:
$-125.29M
1 W Prestazione:
+10.79%
1M Prestazione:
+26.02%
6M Prestazione:
+24.05%
1 anno Prestazione:
-41.08%
Intervallo 1D:
$0.856
$1.01
Intervallo di 1 settimana:
$0.8504
$1.05
Portata 52W:
$0.58
$2.485
Allovir Inc Stock (ALVR) Company Profile
Nome
Allovir Inc
Settore
Industria
Telefono
(617) 433-2605
Indirizzo
1100 WINTER STREET, WALTHAM
Allovir Inc Stock (ALVR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2020-08-24 | Iniziato | JP Morgan | Overweight |
| 2020-08-24 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-24 | Iniziato | SVB Leerink | Outperform |
Allovir Inc Borsa (ALVR) Ultime notizie
Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for InvestorsContact The Gross Law Firm - GuruFocus.com
Discovering Opportunities: AlloVir And 2 Other US Penny Stocks - Simply Wall St
Shareholders that lost money on AlloVir, Inc.(ALVR) Urged to Joi - GuruFocus.com
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir - GuruFocus.com
AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely - Simply Wall St
AlloVir, Inc. (NASDAQ:ALVR) Short Interest Update - MarketBeat
ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors to - GuruFocus.com
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AlloVir, Inc. Invest - GuruFocus.com
SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James - GuruFocus.com
SHAREHOLDER ALERT: Levi & Korsinsky Notifies AlloVir, Inc.(ALVR) - GuruFocus.com
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir - GuruFocus.com
Allovir (ALVR) Sees 5.06% Stock Price Surge Amid Mixed Analyst R - GuruFocus.com
Allovir CEO Diana Brainard sells $7,596 in stock - Investing.com
Allovir's general counsel Edward Miller sells $1,082 in stock By Investing.com - Investing.com South Africa
Allovir's general counsel Edward Miller sells $1,082 in stock - Investing.com
Allovir's chief accounting officer Brett Hagen sells $746 in stock - Investing.com
Allovir CFO Vikas Sinha sells $2,649 in stock - Investing.com
Allovir CFO Vikas Sinha sells $2,649 in stock By Investing.com - Investing.com Canada
Allovir's chief accounting officer Brett Hagen sells $746 in stock By Investing.com - Investing.com UK
BK Virus Infection Market Rising Awareness and Innovations Drive Growth | AlloVir, Amplyx Pharmaceuticals - EIN News
Allovir (ALVR) Stock Experiences Significant Decline Amid Negati - GuruFocus.com
Octagon Capital Advisors LP Increases Stake in AlloVir Inc - GuruFocus.com
Allovir CEO Diana Brainard sells shares to cover tax obligations - Investing.com India
Allovir executive sells shares to cover tax withholding obligations By Investing.com - Investing.com Australia
Allovir executive sells shares to cover tax withholding obligations - Investing.com India
Allovir CEO Diana Brainard sells shares to cover tax obligations By Investing.com - Investing.com South Africa
Allovir general counsel sells $307 worth of shares to cover taxes - Investing.com Australia
Allovir general counsel sells $307 worth of shares to cover taxes By Investing.com - Investing.com South Africa
ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. - GlobeNewswire
AlloVir (NASDAQ:ALVR) Shares Up 1% - Defense World
AlloVir, Inc. (NASDAQ:ALVR) Holdings Lowered by Acadian Asset Management LLC - Defense World
AlloVir (NASDAQ:ALVR) Trading 1% Higher - MarketBeat
Kuehn Law Encourages Investors of AlloVir, Inc. to Contact Law Firm - ForexTV.com
Upward Trajectory: AlloVir Inc (ALVR) Posts a Gaine, Closing at 0.78 - The Dwinnex
Investigation announced for Investors who lost money with - openPR
Influenza Pipeline Drugs 2024 | Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG - Barchart
Influenza Pipeline Drugs 2024 | Moderna, SAB Biotherapeutics, - openPR
Head to Head Analysis: Vaxcyte (NASDAQ:PCVX) & AlloVir (NASDAQ:ALVR) - Defense World
Allovir CEO Diana Brainard sells shares worth nearly $4,000 - Investing.com India
Allovir CEO Diana Brainard sells shares worth nearly $4,000 By Investing.com - Investing.com Australia
Allovir executive sells shares to cover tax obligations - Investing.com
Allovir CEO Diana Brainard sells shares worth over $2,300 - Investing.com
Vanguard Group Inc. Lowers Position in AlloVir, Inc. (NASDAQ:ALVR) - Defense World
Price T Rowe Associates Inc. MD Buys 54,900 Shares of AlloVir, Inc. (NASDAQ:ALVR) - Defense World
ALVR (AlloVir) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
AlloVir (NASDAQ:ALVR) Posts Earnings Results, Beats Expectations By $0.05 EPS - Defense World
B of A Securities Initiates Coverage of AlloVir (ALVR) with Buy Recommendation - MSN
Seasonal Influenza Treatment Market Size 2032 | SAb - openPR
Analyzing Immunovant (NASDAQ:IMVT) & AlloVir (NASDAQ:ALVR) - Defense World
AlloVir Inc (ALVR) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely - Yahoo Finance
Allovir Inc Azioni (ALVR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):